BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16158275)

  • 1. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.
    Labarthe MC; Halanek N; Birchall L; Russell N; Desel C; Todryk S; Peters MJ; Lucas A; Falkenberg FW; Dalgleish AG; Whelan M; Ward SJ
    Cancer Immunol Immunother; 2006 Mar; 55(3):277-88. PubMed ID: 16158275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.
    Todryk SM; Birchall LJ; Erlich R; Halanek N; Orleans-Lindsay JK; Dalgleish AG
    Immunology; 2001 Feb; 102(2):190-8. PubMed ID: 11260324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel murine model of allogeneic vaccination against prostate cancer.
    Labarthe MC; Theocharous P; Russell N; Todryk S; Bangma C; Thraves P; Dalgleish AG; Whelan MA
    Cancer Immunol Immunother; 2008 Apr; 57(4):453-65. PubMed ID: 17805533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
    Aruga A; Aruga E; Chang AE
    Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine.
    Knight BC; Souberbielle BE; Rizzardi GP; Ball SE; Dalgleish AG
    Melanoma Res; 1996 Aug; 6(4):299-306. PubMed ID: 8873049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.
    Kircheis R; Küpcü Z; Wallner G; Rössler V; Schweighoffer T; Wagner E
    Cancer Gene Ther; 2000 Jun; 7(6):870-8. PubMed ID: 10880017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells.
    Schneeberger A; Lührs P; Kutil R; Steinlein P; Schild H; Schmidt W; Stingl G
    J Immunol; 2003 Nov; 171(10):5180-7. PubMed ID: 14607918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells.
    Kim TS; Jung MY; Cho D; Cohen EP
    Vaccine; 2006 Oct; 24(42-43):6564-73. PubMed ID: 16837111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
    Mac Keon S; Bentivegna S; Levy EM; Marks MS; Mantegazza AR; Wainstok R; Mordoh J
    Vaccine; 2019 Aug; 37(35):4947-4955. PubMed ID: 31307876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine.
    Li H; Jiang HJ; Ma MQ; Wei F; An XM; Ren XB
    Cancer Biother Radiopharm; 2007 Dec; 22(6):790-8. PubMed ID: 18158770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
    Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of murine melanoma growth by granulocyte-macrophage colony stimulating factor gene transfection is not haplotype specific.
    Botella R; Sarradet MD; Potter LE; Lawley M; Galloway TH; Ansel JC; Armstrong CA
    Melanoma Res; 1998 Jun; 8(3):245-54. PubMed ID: 9664146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
    Kim TS; Russell SJ; Collins MK; Cohen EP
    Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine.
    Souberbielle BE; Knight BC; Morrow WJ; Darling D; Fraziano M; Marriott JB; Cookson S; Farzaneh F; Dalgleish AG
    Gene Ther; 1996 Oct; 3(10):853-8. PubMed ID: 8908498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.
    Eisenthal A; Skornick Y; Merimsky O; Hirsch R; Zakut V; Ron I; Chaitchik S
    Cancer Immunol Immunother; 1993 Sep; 37(4):233-9. PubMed ID: 8348562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
    Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
    Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
    Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.